Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan O'Brien

Showing results (31-40 of 643) with videos related to

Pageof 65
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2016
First-line therapy for young patients with CLLNitin Jain, Susan O'Brien
Oncology (Williston Park, N.Y.)|November 18, 2016
The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic LeukemiaDeepa Jeyakumar, Susan O'Brien
Future Oncology (London, England)|November 2, 2018
Acalabrutinib and its use in treatment of chronic lymphocytic leukemiaYasir Khan, Susan O'Brien
Blood|November 5, 2016
BCR inhibitor failure in CLL: an unmet needNitin Jain, Susan O'Brien
Blood Reviews|January 19, 2016
Targeted therapies for CLL: Practical issues with the changing treatment paradigmNitin Jain, Susan O'Brien
Blood Advances|December 29, 2021
Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKisElizabeth A Brem, Susan O'Brien
Targeted Oncology|April 4, 2009
Targeted therapy for chronic lymphocytic leukemiaAlfonso Quintás-Cardama, Susan O'Brien
Medical Oncology (Northwood, London, England)|December 8, 2004
Monoclonal antibodies in the treatment of chronic lymphocytic leukemiaNina Shih Liu, Susan O'Brien
JCO Oncology Practice|July 21, 2021
Frontline Management of CLL in 2021Elizabeth A Brem, Susan O'Brien
Drugs of Today (Barcelona, Spain : 1998)|September 16, 2003
Monoclonal antibodies in the treatment of lymphoid leukemiaSusan O'Brien, Francis J Giles
Pageof 65

Showing results (31-40 of 643) with videos related to

Sort By:
Pageof 65
Hematology. American Society of Hematology. Education Program|December 4, 2016
First-line therapy for young patients with CLLNitin Jain, Susan O'Brien
Oncology (Williston Park, N.Y.)|November 18, 2016
The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic LeukemiaDeepa Jeyakumar, Susan O'Brien
Future Oncology (London, England)|November 2, 2018
Acalabrutinib and its use in treatment of chronic lymphocytic leukemiaYasir Khan, Susan O'Brien
Blood|November 5, 2016
BCR inhibitor failure in CLL: an unmet needNitin Jain, Susan O'Brien
Blood Reviews|January 19, 2016
Targeted therapies for CLL: Practical issues with the changing treatment paradigmNitin Jain, Susan O'Brien
Blood Advances|December 29, 2021
Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKisElizabeth A Brem, Susan O'Brien
Targeted Oncology|April 4, 2009
Targeted therapy for chronic lymphocytic leukemiaAlfonso Quintás-Cardama, Susan O'Brien
Medical Oncology (Northwood, London, England)|December 8, 2004
Monoclonal antibodies in the treatment of chronic lymphocytic leukemiaNina Shih Liu, Susan O'Brien
JCO Oncology Practice|July 21, 2021
Frontline Management of CLL in 2021Elizabeth A Brem, Susan O'Brien
Drugs of Today (Barcelona, Spain : 1998)|September 16, 2003
Monoclonal antibodies in the treatment of lymphoid leukemiaSusan O'Brien, Francis J Giles
Pageof 65